

Community Counts: Exploring Transcription Regulation & Immunotherapy for ES-SCLC

Clinical Case #3 References

Ahmed Y. 89P The role of palliative care in extensive stage lung cancer. *J Thorac Oncol*. 2018;13(4):S49. doi:10.1016/s1556-0864(18)30364-2

Balboni TA, Hui KP, Kamal AH. Supportive care in lung cancer: improving value in the era of modern therapies. *Am Soc Clin Oncol Educ Book*. 2018;38:716-725. doi:10.1200/EDBK_201369

Ferrell BR, Temel JS, Temin S, et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology Clinical Practice Guideline update. *J Clin Oncol*. 2017;35(1):96-112. doi:10.1200/JCO.2016.70.1474

Fulton JJ, LeBlanc TW, Cutson TM, et al. Integrated outpatient palliative care for patients with advanced cancer: a systematic review and meta-analysis. *Palliat Med*. 2019;33(2):123-134. doi:10.1177/0269216318812633

Horn L, Mansfield AS, Szczesna A, et al. First-Line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. *N Engl J Med*. 2018;379(23):2220-2229. doi:10.1056/NEJMoa1809064

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Cancer-Related Fatigue (v1.2021). Updated December 1, 2020. Accessed December 8, 2021. https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Hematopoietic Growth Factors (v4.2021). Updated May 20, 2021. Accessed December 9, 2021. https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Palliative Care (v2.2021). Updated February 12, 2021. Accessed September 29, 2021. https://www.nccn.org/professionals/physician_gls/pdf/palliative.pdf

Sullivan DR, Chan B, Lapidus JA, et al. Association of early palliative care use with survival and place of death among patients with advanced lung cancer receiving care in the Veterans Health Administration. *JAMA Oncol*. 2019;5(12):1702-1709. doi:10.1001/jamaoncol.2019.3105

Tobian AA, Heddle NM, Wiegmann TL, Carson JL. Red blood cell transfusion: 2016 clinical practice guidelines from AABB. *Transfusion*. 2016;56(10):2627-2630. doi:10.1111/trf.13735

Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. *Lancet Oncol*. 2020;21(5):645-654. doi:10.1016/s1470-2045(20)30068-1

ZEPZELCA™ (lurbinectedin) [prescribing information]. Jazz Pharmaceuticals, Inc. Approved 2020. Revised June 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf

Glossary

3L, third line
AABB, Association for the Advancement of Blood and Biotherapies
ADL, activity of daily living
AEs, adverse event
aLC, advanced lung cancer
ALT, alanine aminotransferase
ASCO, American Society of Clinical Oncology
AST, aspartate aminotransferase
Atezo, atezolizumab
CBT, cognitive behavioral therapy
Chemo, chemotherapy
CI, confidence interval
CT, computed tomography
DOR, duration of response
Endo, endocrinology
EOL, end of life
ES, extensive stage
GVHD, graft-versus-host disease
Hb, hemoglobin
IO, immunotherapy
IV, intravenous
Lurbi, lurbinectedin
mDOR, median duration of response
mOS, median overall survival
mPFS, median progression-free survival
MRI, magnetic resonance imaging
OS, overall survival
PC, palliative care
PFS, progression-free survival
Pts, patients
QOL, quality of life
RBC, red blood cell
SCLC, small cell lung cancer
SMD, standardized mean difference
T4, thyroxine
TSH, thyroid-stimulating hormone
Tx, treatment
w/, with